GlassScriptPhysician profile
Roopali Gupta
NPI 1649478462
$3,994.96
in general payments reported to CMS, 2019-2025
24 companies · $1,173 in 2025
The $1,173 reported for 2025 was more than what 81% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $577 · 2020: $99.09 · 2021: $269 · 2022: $375 · 2023: $577 · 2024: $925 · 2025: $1,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,464 · Education: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,464.23 |
| Education | $210.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $716.00 | 2023-2025 | Ibsrela, Xphozah 30 Mg |
| Fresenius USA Marketing, INC. | $604.64 | 2019-2025 | Velphoro, Velphoro |
| Amgen INC. | $449.15 | 2019-2025 | Krystexxa, Parsabiv, Aranesp |
| Astrazeneca Pharmaceuticals LP | $305.30 | 2019-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $253.78 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $249.71 | 2021-2025 | |
| Akebia Therapeutics INC | $233.91 | 2019-2025 | Vafseo, Auryxia |
| E.R. Squibb & Sons, L.L.C. | $160.90 | 2019-2020 | |
| Opko Pharmaceuticals, LLC | $157.78 | 2019-2023 | Rayaldee |
| Aurinia Pharma U.S., INC. | $130.36 | 2022-2025 | Lupkynis |
| Seagen INC. | $99.95 | 2024 | |
| Glaxosmithkline, LLC. | $97.66 | 2021-2024 | Benlysta, Jesduvroq |
| Lilly USA, LLC | $92.36 | 2022-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $75.53 | 2019-2025 | Jynarque |
| Mallinckrodt Enterprises LLC | $74.99 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $60.51 | 2022-2023 | Tarpeyo |
| Ani Pharmaceuticals, INC. | $56.91 | 2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.51 | 2023-2025 | Jardiance |
| Vifor Pharma, INC. | $38.67 | 2022-2023 | Veltassa |
| Biomerieux INC | $31.45 | 2021 | |
| Mallinckrodt Hospital Products INC. | $15.52 | 2021 | |
| Novo Nordisk INC | $15.34 | 2025 | Ozempic |
| Shire North American Group INC | $12.53 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roopali Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.